Engineering extracellular vesicles for Alzheimer's disease: An emerging cell‐free approach for earlier diagnosis and treatment
Year: 2021
Type: review
Abstract: Alzheimer's disease (AD) is a debilitating neurodegenerative disorder affecting over five million people globally and has no established cure. Current AD-related treatments only alleviate cognitive and behavioral symptoms and do not address disease onset or progression, underlining the unmet need to create an effective, innovative AD therapeutic. Extracellular vesicles (EVs) have emerged as a new class of nanotherapeutics. These secreted, lipid-bound cellular signaling carriers show promise for potential clinical applications for neurodegenerative diseases like AD. Additionally, analyzing contents and characteristics of patient-derived EVs may address the unmet need for earlier AD diagnostic techniques, informing physicians of altered genetic expression or cellular communications specific to healthy and diseased physiological states. There are numerous recent advances in regenerative medicine using EVs and include bioengineering perspectives to modify EVs, target glial cells in neurodegenerative diseases like AD, and potentially use EVs to diagnose and treat AD earlier. This article is categorized under: Neurological Diseases > Biomedical Engineering Neurological Diseases > Molecular and Cellular Physiology Neurological Diseases > Stem Cells and Development.
Source: WIREs Mechanisms of Disease
DOI: 10.1002/wsbm.1541
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
Funders: School of Veterinary Medicine, University of California, Davis, Shriners Hospitals for Children, National Institutes of Health, University of California, Davis, National Institute on Aging, National Institute of Neurological Disorders and Stroke, National Center for Advancing Translational Sciences, Eunice Kennedy Shriver National Institute of Child Health and Human Development
Awards: G1083396249, UC Davis Alzheimer's Disease Core Center, G1636620865, G203354908, G2659888700, G2826625206, G3608626411, G3694532710, G3847428086, Guinea pigs as a model of in utero stem cell therapy for spina bifida, G420600422, Fetal Tissue Engineering to Treat Spina Bifida Before Birth, G477963360, Engineered Neuroprotective Stem-Cell Exosomes for In Utero Spina Bifida Therapy, G4996605879, G547291771, G5852404115, G6754129548, G7158873286, G7329987156, G747583580, UC Davis Clinical and Translational Science Center, NRSA Training Core (TL1)
OpenAlex ID: W3205379543